Lower urinary tract symptoms (LUTS) in males with type 2 diabetes recently treated with SGLT2 inhibitors—overlooked and overwhelming? A retrospective case series
- 292 Downloads
As outlined in the latest recommendations for patients with type 2 diabetes (DM2), sodium glucose cotransporter 2 inhibitors (SGLT2i) can be added on treatments with metformin or sulfonylurea plus metformin if glycemic goals are not met . Genital and urinary infections are well-known side effects of SGLT2i, with reported odds ratios in the range of 3.21–5.23, compared with placebo [2, 3].
Lower urinary tract symptoms (LUTS) are urological complications occurring in patients with DM2—males in particular—, whereas little is known about their prevalence in patients treated with SGLT2i . This association is of particular interest because a symptom such as polyuria—often reported by patients starting treatment with SGLT2i—may be the sign of a urological predisposing conditions, rather than a side effect of a new treatment.
Hence this case-series on male patients who had recently started treatment with SGLT2i, to assess the prevalence of new-onset LUTS. We documented any...
Compliance with ethical standards
Conflict of interest
The authors declare that they have no competing interests.
- 2.D. Li, T. Wang, S. Shen, Z. Fang, Y. Dong, H. Tang, Urinary tract and genital infections in patients with type 2 diabetes treated with sodium-glucose co-transporter 2 inhibitors: a meta-analysis of randomized controlled trials. Diabetes Obes. Metab. Epub ahead of print (2016)Google Scholar
- 3.W.T. Cefalu, L.A. Leiter, K.H. Yoon et al. Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial. Lancet 382, 941–950 (2013)CrossRefGoogle Scholar